OncoSil Medical Achieves Milestones in Two Pancreatic Cancer Trials; Shares Up 8%

MT Newswires Live

Sep 27, 2024

OncoSil Medical (ASX:OSL) achieved 50% of its target recruits for its TRIPP-FFX clinical trial, with the 40th patient randomized, according to a Thursday filing with the Australian bourse.

The trial aims to assess the safety and efficacy of OncoSil when given in addition to standard Folfirinox chemotherapy in treating locally advanced pancreatic cancer, the filing stated.

Meanwhile, the company reached the halfway point of patient recruitment in its Pancosil clinical trial, with the 10th patient treated, the filing said.

The trial is evaluating the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil device in patients with non-progressive locally advanced pancreatic cancer.

The medical device company's shares surged almost 8% in recent Friday trade.

Price (AUD): $0.01, Change: $+0.0010, Percent Change: +7.69%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2470675749"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2470675749\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2470675749?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-27 11:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470675749","market":"fut","top_or_hot":-1,"title":"OncoSil Medical Achieves Milestones in Two Pancreatic Cancer Trials; Shares Up 8%","media":"MT Newswires Live","content":"<html><body><p> OncoSil Medical (ASX:OSL) achieved 50% of its target recruits for its TRIPP-FFX clinical trial, with the 40th patient randomized, according to a Thursday filing with the Australian bourse.</p><p>The trial aims to assess the safety and efficacy of OncoSil when given in addition to standard Folfirinox chemotherapy in treating locally advanced pancreatic cancer, the filing stated.</p><p>Meanwhile, the company reached the halfway point of patient recruitment in its Pancosil clinical trial, with the 10th patient treated, the filing said.</p><p>The trial is evaluating the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil device in patients with non-progressive locally advanced pancreatic cancer.</p><p>The medical device company's shares surged almost 8% in recent Friday trade.</p><p>Price (AUD): $0.01, Change: $+0.0010, Percent Change: +7.69%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OncoSil Medical Achieves Milestones in Two Pancreatic Cancer Trials; Shares Up 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncoSil Medical Achieves Milestones in Two Pancreatic Cancer Trials; Shares Up 8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-09-27 11:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> OncoSil Medical (ASX:OSL) achieved 50% of its target recruits for its TRIPP-FFX clinical trial, with the 40th patient randomized, according to a Thursday filing with the Australian bourse.</p><p>The trial aims to assess the safety and efficacy of OncoSil when given in addition to standard Folfirinox chemotherapy in treating locally advanced pancreatic cancer, the filing stated.</p><p>Meanwhile, the company reached the halfway point of patient recruitment in its Pancosil clinical trial, with the 10th patient treated, the filing said.</p><p>The trial is evaluating the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil device in patients with non-progressive locally advanced pancreatic cancer.</p><p>The medical device company's shares surged almost 8% in recent Friday trade.</p><p>Price (AUD): $0.01, Change: $+0.0010, Percent Change: +7.69%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2470675749","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470675749","pubTimestamp":1727408601,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"OncoSil Medical  achieved 50% of its target recruits for its TRIPP-FFX clinical trial, with the 40th patient randomized, according to a Thursday filing with the Australian bourse.The trial aims to assess the safety and efficacy of OncoSil when given in addition to standard Folfirinox chemotherapy in treating locally advanced pancreatic cancer, the filing stated.Meanwhile, the company reached the halfway point of patient recruitment in its Pancosil clinical trial, with the 10th patient treated, the filing said.The trial is evaluating the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil device in patients with non-progressive locally advanced pancreatic cancer.The medical device company's shares surged almost 8% in recent Friday trade.Price : $0.01, Change: $+0.0010, Percent Change: +7.69%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","OSL.AU":"ONCOSIL MEDICAL LTD","BK4125":"广播","BK7048":"生命科学工具和服务"},"translate_title":"OncoSil Medical在两项胰腺癌试验中实现里程碑；股价上涨8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"OSL.AU":0.9},"content_text":"OncoSil Medical (ASX:OSL) achieved 50% of its target recruits for its TRIPP-FFX clinical trial, with the 40th patient randomized, according to a Thursday filing with the Australian bourse.The trial aims to assess the safety and efficacy of OncoSil when given in addition to standard Folfirinox chemotherapy in treating locally advanced pancreatic cancer, the filing stated.Meanwhile, the company reached the halfway point of patient recruitment in its Pancosil clinical trial, with the 10th patient treated, the filing said.The trial is evaluating the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil device in patients with non-progressive locally advanced pancreatic cancer.The medical device company's shares surged almost 8% in recent Friday trade.Price (AUD): $0.01, Change: $+0.0010, Percent Change: +7.69%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}